Neutrophil-to-Lymphocyte Ratio in Gout Suggests Sustained Post-Flare Inflammation
At the 2022 American College of Rheumatology Convergence meeting, Michael Pillinger, MD, presented...
Read MoreNov 29, 2022
At the 2022 American College of Rheumatology Convergence meeting, Michael Pillinger, MD, presented...
Read MoreNov 29, 2022
For patients with irritable bowel syndrome with diarrhea (IBS-D), symptoms such as abdominal pain...
Read MoreNov 29, 2022
A direct relationship frequently exists between income and investment opportunity. However,...
Read MoreNov 25, 2022
For patients with migraine, poor sleep quality contributes to increased migraine risk and migraine...
Read MoreNov 23, 2022
“Your blood sugar is high, but your salt, pepper, ketchup, mustard and grated cheese levels...
Read MoreNov 23, 2022
Olfactory dysfunction following total laryngectomy decreased QOL for patients, especially among...
Read MoreNov 18, 2022
Gout flares occurred in 18% of patients with comorbid gout who were hospitalized for COVID-19,...
Read MoreNov 17, 2022
According to a British Medical Journal analysis, medical errors occur quite frequently, annually...
Read MoreNov 16, 2022
When three-dose schedule antibody concentrations are reached in patients with blood cancer who are...
Read MoreNov 16, 2022
“What fits your busy schedule better, exercising 1 hour a day or being dead 24 hours a...
Read MoreNov 15, 2022
IgG-based elimination diets using a novel diagnostic tool to guide therapy may be beneficial to...
Read MoreNov 15, 2022
For patients with gout, urate-lowering therapy (ULT) increases the risk of hospitalizations within...
Read MoreNov 15, 2022
Individuals with hypercholesterolemia who had higher levels of campesterol experienced...
Read MoreNov 15, 2022
Limited research has been done on outcomes after the return of secondary findings in large-scale...
Read MoreNov 15, 2022
Tafolecimab provided significant, durable decreases in low-density lipoprotein cholesterol (LDL-C)...
Read MoreNov 15, 2022
VICTORION-INCEPTION is a phase IIIb, randomized, parallel-group, open-label, multicenter, US-based...
Read MoreNov 15, 2022
The principal finding from a 4-year open-label extension study of inclisiran—a small interfering...
Read MoreNov 15, 2022
For patients with refractory/relapsed acute myeloid leukemia (AML), total therapy, as compared...
Read More